107.24
price up icon0.73%   0.78
pre-market  Pre-mercato:  106.53   -0.71   -0.66%
loading

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
Apr 29, 2025

Asia-Pacific Tourette Syndrome Treatment Market Report - openPR.com

Apr 29, 2025
pulisher
Apr 29, 2025

Neurocrine Biosciences publishes positive data from movement disorder study - MSN

Apr 29, 2025
pulisher
Apr 28, 2025

Neurocrine Sues Zydus to Guard Ingrezza’s New Sprinkle Form - Bloomberg Law News

Apr 28, 2025
pulisher
Apr 28, 2025

Canaccord cuts Neurocrine Bio stock target to $158, keeps Buy rating - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards? - Yahoo Finance

Apr 28, 2025
pulisher
Apr 28, 2025

Neurocrine (NBIX) Sees Price Target Adjustment Amid Market Volat - GuruFocus

Apr 28, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

Neurocrine Highlights INGREZZA's Long-Term Efficacy & Safety In Older Adults With Tardive Dyskinesia - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Neurocrine Biosciences publishes positive data from movement disorder study (NBIX:NASDAQ) - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

Neurocrine (NBIX) Highlights Efficacy of Ingrezza in Older Adults with Tardive Dyskinesia | NBIX Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry - PR Newswire

Apr 24, 2025
pulisher
Apr 23, 2025

Neurocrine (NBIX) Target Price Lowered by H.C. Wainwright Due to Market Pressures | NBIX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 22, 2025

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 - Seeking Alpha

Apr 22, 2025
pulisher
Apr 22, 2025

Neurocrine Bio shares target cut to $168 by H.C. Wainwright - Investing.com India

Apr 22, 2025
pulisher
Apr 22, 2025

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case - Yahoo Finance

Apr 22, 2025
pulisher
Apr 21, 2025

Neurocrine Biosciences director sells shares worth $21.8 million - MSN

Apr 21, 2025
pulisher
Apr 20, 2025

Neurocrine upgraded at RBC Capital Markets on recent selloff - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

Do Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Warrant Your Attention? - simplywall.st

Apr 18, 2025
pulisher
Apr 17, 2025

(NBIX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (NBIX) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Needham Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq

Apr 16, 2025
pulisher
Apr 15, 2025

Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

What 16 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Needham Upgrades Neurocrine Biosciences (NBIX) - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - marketscreener.com

Apr 15, 2025
pulisher
Apr 14, 2025

RBC Capital Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Capital lifts Neurocrine Bio. stock rating to Outperform By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Kilgore News Herald

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Capital Upgrades Neurocrine Biosciences (NBIX) - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine stock upgraded at RBC Capital Markets (NBIX:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

RBC upgrades Neurocrine Biosciences on low tariff exposure for key drug - TradingView

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138 - MarketScreener

Apr 14, 2025
pulisher
Apr 09, 2025

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

Apr 09, 2025
pulisher
Apr 08, 2025

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Tourette Syndrome Treatment Market Generated Opportunities, - openPR.com

Apr 08, 2025
pulisher
Apr 05, 2025

Neurocrine Biosciences names Sanjay Keswani as chief medical officer - MSN

Apr 05, 2025
pulisher
Apr 05, 2025

Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

NBIXNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - ADVFN

Apr 04, 2025
pulisher
Apr 04, 2025

Ex-Dyne team members reconvene at Crescent - biocentury.com

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints New Chief Medical Officer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com Canada

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medi - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences names new Chief Medical Officer - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - marketscreener.com

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider

Apr 04, 2025
pulisher
Apr 04, 2025

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer – Company Announcement - Financial Times

Apr 04, 2025
pulisher
Apr 04, 2025

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating - MarketScreener

Apr 04, 2025
$8.34
price up icon 1.09%
drug_manufacturers_specialty_generic RDY
$13.94
price up icon 0.00%
$300.76
price up icon 1.25%
$103.96
price up icon 1.23%
$28.77
price up icon 3.08%
Capitalizzazione:     |  Volume (24 ore):